B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer.

"additional file 2 : fig s6c). fig 2 association dot plot all data"

"Declarations Ethics approval and consent to participateThis study was approved by the Review Board of the Netherlands Cancer Institute and conducted in accordance with the Declaration of Helsinki. No informed consent was required. Consent for publicationNot applicable. Competing interestsGS reports institutional research support from AstraZeneca, Merck, Novartis, and Roche outside the scope of this manuscript. HMH reports institutional research support from Roche outside the scope of this manuscript. RS reports non-financial support from Merck and Bristol Myers Squibb; research support from Merck, Puma Biotechnology, and Roche; and personal fees from Roche for an advisory board related to a trial-research project. MK reports institutional research support from AstraZeneca, BMS, Roche outside the scope of this manuscript. MK is advisory board member for BMS, Daiichi, MSD and Roche (compensated to the institute). LM and RB are employed by Agendia the commercial entity that markets the 70-gene signature as MammaPrint. LV is co-founder, stockholder and part-time employed by Agendia the commercial entity that markets the 70-gene signature as MammaPrint. TS, DW, MC, JS, SC, BT, CY, NO, AB, GH, JPC, and HH report no conflict of interest. Competing interests GS reports institutional research support from AstraZeneca, Merck, Novartis, and Roche outside the scope of this manuscript. HMH reports institutional research support from Roche outside the scope of this manuscript. RS reports non-financial support from Merck and Bristol Myers Squibb; research support from Merck, Puma Biotechnology, and Roche; and personal fees from Roche for an advisory board related to a trial-research project. MK reports institutional research support from AstraZeneca, BMS, Roche outside the scope of this manuscript. MK is advisory board member for BMS, Daiichi, MSD and Roche (compensated to the institute). LM and RB are employed by Agendia the commercial entity that markets the 70-gene signature as MammaPrint. LV is co-founder, stockholder and part-time employed by Agendia the commercial entity that markets the 70-gene signature as MammaPrint. TS, DW, MC, JS, SC, BT, CY, NO, AB, GH, JPC, and HH report no conflict of interest."

"Funding This project was supported with grants from A Sister’s Hope, [Z]aan de Wandel, Nijbakker-Morra, Jo Kolk and Atwater Foundation. RS is supported by a grant of the Breast Cancer Research Foundation (BCRF), Grant No. 17-194."